Project Report CFA
Project Report CFA
Project Report CFA
category
development
INITIATING COVERAGE , building
EQUITY brands and
improving
penetration,
rewiring
GTM, etc.
The CEO Factor Payoff may
take time but
Appointment of Sudhir as MD & looks more
CEO and Dharnesh as GAUM
cluster head reflects hunger to
sustainable.
work on missing pieces –
category development, Diagnosing
innovation and recalibrating GTM issues
GTM. Task is arduous but most of
concerns seem internal, hence international
fixable. Outcome of initial steps business (IB)
(e.g. rewiring distribution in GCPL’s IB
GAUM) are encouraging and as revenues
execution improves, albeit over FY17-21
gradually (turnaround in HI will posted 2%
take ~12 months), we expect CAGR. Poor
11%/13% revenue/EBITDA CAGR growth was
over FY21-25E vs 6%/8% over due to weak
FY16-21. This along with GTM model,
controlled capex (capital both in
employed CAGR of 10%) should GAUM
improve RoCE by ~1,300bps over (Godrej
FY21-25E. In the longer term, Africa, USA,
pivot into larger home care and Middle-East)
cross-pollination opportunities and
would provide growth longevity. Indonesia.
Risks: Delay in breakthrough Appointment
innovation in HI and macro- of new
economic concerns in cluster head
GAUM/Indonesia. with a core
KPI of re-
Competitive position: STRONG wiring GTM
(initial results
Changes to this position: STABLE encouraging,
exhibit 63)
Transitioning to a sustainable makes us
growth mindset believe
GCPL’s FY05-17 revenue CAGR growth
was led more by acquisitions trajectory for
(domestic + IB) than category IB can inch
development, premiumisation, back to ~12%
forays in adjacencies etc. With CAGR over
the new MD & CEO and
geography cluster head in place, FY21-25E.
aspiration to deliver double-digit
revenue growth remains but
would be led by focus on
Godrej Consumer
BUY 1
5
March 28, 2022 0
100
0
a
n
t
.
Source: Bloomberg, Ambit Capital Research s
a
t
i
y
a
@
a
m
b
i
Research Analysts
t
Alok Shah, CFA
.
+91 22 6623
c
3259
o
alok.shah@ambi
t.co
abhishek.ra
2022-03-28 Monday 10:00:10
The Narrative in
Charts
Exhibit 1: 12% topline CAGR in the last decade was led by
double-digit domestic growth (till FY16) and acquisitions in
IB; EBITDAM expanded 294bps but goodwill and moderate
IB performance (post inorganic phase) led to RoCE
contraction
Pivotin
chann
mix,
addres
compe
tive
pressu
s a
macro
Akhil Chandra Business Head - ASEAN
15 %
12 %
11 % 11 %
12 % 11 % 11 %
9%
6% 5%
3%
0%
FY21
FY23E
FY22E
FY24E
FY16-21
CAGR
Source: Company, Ambit Capital research;
10 %
8%
6%
4%
2%
0%
Rev CAGR EBITDA CAGR PAT CAGR
60 x
Nestle
50 x
FY24 P/E
Dabur HU L
40 x Marico Tata
Consumer
30 x Britanni a
GCPL
20 x
10 % 15 % 20 % 25 % 3
PAT CAGR FY22-24E
Domestic
business: Strategy
in place,
execution to
follow
GCPL’s
India
portfolio
comprises
highly
penetrate
d (soaps)
and
lowpenetr
ated (HI,
air care,
hair
colour)
categories
, requiring
efforts to
increase
penetratio
n and
market
size.
While
growth in
soaps has
been
strong
(10%
CAGR
over FY11-
21 with
share
gains),
category
developm
ent in low
penetrate
d
categories
has not
been
sufficient.
It is
heartenin
g to see
GCPL’s
board
appointin
g Sudhir
Sitapati as
MD &
CEO, who
has
relevant
experienc
e in
seeding
brands/ca
tegories.
His
renewed
strategy
of
focusing
on
breakthro
ugh
innovatio
n, upping
category
developm
ent
through
increasing
ad
spends,
and
improving
efficiency
&
productivi
ty should
improve
growth
from mid-
single
digit
(FY17-21)
to low
double
digit (11%
domestic
revenue
CAGR
over FY21-
25E). In
HI, GCPL
will need
to address
product
efficacy
concerns
(successfu
lly done
over FY11-
15). In
soaps, it
will need
to
maintain
status quo
in
seamlessl
y working
current
strategy.
In hair
colour, air
care and
other
smaller
portfolios,
focus on
category
developm
ent and
penetratio
n-led
growth if
required.
FY21 Other
5%
India, Personal
55% care,
Internat ional, 46 %
45%
Household
insecticides –
Product
innovation and
brand spends
are a prudent
move
The HI
category
size in
India is
~`65bn,
which has
grown at
6-7%
CAGR over
the last 5-
6 years.
Majority
(87%) of
the HI
market is
for
mosquitoe
s, with
liquid
vaporizer
(LV) and
coils
accountin
g for ~60%
of the
overall HI
market.
While
overall
category
penetratio
n is ~60%
+, major
sub-
categories
of LV and
coils have
penetratio
n of just
~25%/32%
(with
limited
overlap),
offering
scope to
expand
the
category
led by
increase in
penetratio
n.
Exhibit 14: LV and coils account for ~60% of the HI market
in India
Sub-category Size (` bn) Last 5y
Liquid vaporizer 23bn 3-4
Others
(Mortein, Liquid vaporizer local
players),
6%
Maxo, 9%
GoodKnight
All Out, , 55%
30 %
of illegal
incense
sticks and
possible
lower ad
spends by
GCPL.
Illegal
incense
sticks have
been
growing at
15-20%
CAGR
owing to
high
efficacy
and longer
life (vs
incumbent
s), quick
results
(drop
dead
instantly)
and lack of
consumer
awareness
regarding
their
harmful
effects on
health.
While the
governme
nt is trying
to tackle
these
incense
sticks
through
regulatory
curbs,
success
has been
low as the
incense
sticks
category
has
maintaine
d its
double-
digit
growth
trajectory.
30,000
2% CAGR
25,000
20,000
15,000
10,000
5,000
0
FY11
FY12
FY13
FY14
FY15
FY16
FY17
FY18
FY19
FY20
FY21
Source: Company, Ambit Capital research
Capital research
Under the
new
managem
ent, GCPL
is banking
on
category
developm
ent
initiatives
to drive
penetratio
n-led
growth for
the HI
category.
To gauge
the
probabilit
y of
success,
we
analyze
the HI
category
across a
few
parameter
s:
Category
relevance
&
consumer
behavior
– Use
case
prevails
but GCPL
needs to
undertak
e
stronger
messagin
g
HI
category
would
remain
relevant
as
mosquito-
borne
diseases
like
malaria
and
dengue
continue
to plague
India. As
disposable
income
and
standard
of living
improve,
basis
global
playbook
(refer
below
exhibit),
more
consumer
s should
get
recruited
into the HI
category.
Exhibit 19: India has one of the lowest per capita HI spends, signifying growth potential; as GDP per in the last decade, only a few have
capita increases, HI category spends should move up met with success. This is because most
of the innovation has been
incremental rather than
breakthrough. Amongst the recent
launches (i) Gold flash has been
successful due to higher efficacy: (ii)
Neem
Amb
Ltd.
To correct this consumer behavior
change from being reactive to
proactive, category participants will
need to significantly invest behind
relevance, improve efficacy and
undertake product innovation.
Source: Company
However, one of the challenges of the HI category is the reactive nature of consumers and trust
on the efficacy of HI products. This limits the usage of HI products and brings seasonality to the
category, i.e. higher usage during monsoon when mosquito incidence is high. 2Q and 3Q
account for 55-60% of annual HI sales for GCPL. Changing consumer behavior from reactive to
proactive is required but not easy.
Affordability – GCPL to bring perception change of LV being higher price product vs coils
Coil as a format has higher saliency in rural (50-60% penetration) than LV as people tend to
sleep outdoors, electrification issues (though this issue is largely behind) and lower prices of coil
vs LV. While optically coil seems to be more affordable compared to LV (high upfront
investment), on a cost per night basis, LV is priced at par if not cheaper (refer below exhibit).
Hence, higher awareness regarding LV affordability is needed.
Exhibit 20: LV is cheaper than coil on a costs/night basis
Product Pack size Price (`) `/night Comments
GoodKnight Neem 180 1.5 Assuming only 1 agarbatti used per night (1
Pack of 120 agarbatti lasts for 3 hours)
Agarbatti
GoodKnight Coil 36 3.6 Assuming 1 coil per night (coil lasts for 10-12 hours)
Pack of 10
Activ+
Assuming 1 refill pack works for a month (810
GoodKnight Gold
95 3.2 hours use/night). Every additional refill costs `77
Machine + 1 refill Flash
(i.e. `2.6/night)
Source: Company, Ambit Capital research; Note – We have considered MRP while calculating the `/night
Going forward, as per the new management’s strategy, GCPL will focus on fewer launches but suggests 50-55% GM (refer below
more breakthrough innovation, which we believe is the right strategy. This also means, until a exhibit) for the LV category. Basis
new breakthrough product is launched, expecting a sustained double-digit growth in HI would channel checks, we understand that
be too optimistic. margins in burning formats such as
coils are much lower due to higher
Another critical thing to note in product innovation is that the main active ingredient for LV
trade margins, hence the efforts from
products is manufactured by a single chemical company and all Indian LV players source from
companies to upgrade consumers
that company. Thus, GCPL’s ability to differentiate the product solely basis the ingredient may
from coil to LV. While GCPL is focusing
be limited. This potentially means GCPL’s breakthrough innovation would be a function of
on LV as a format, increase in sales of
innovation in the external device of LV vs solely on the liquid.
its refill packs is critical for improving
Exhibit 21: GoodKnight has led innovation in the HI category GM. It is critical to ensure that
competing brands’ refill packs do not
fit in GCPL’s LV device.
Exhibit 22: S.C. Johnson India operates at
50-57% GM; All Out has ~30% market
share in LV and accounts for ~80-85% of
S.C. Johnson’s topline
` mn FY16 F
Sales 7,149 6
Growth % 5.1% -7
Exhibit 23: GCPL’s coil pricing is in line with competition; Exhibit 24: Limited avenue to price refill packs higher important in coil is to ensure higher
trade schemes than competition since it can usually be re-engineered
Pack Price Pack Price Price/
Product Product
size ( in ` .) size ( in ` ) refill
GoodKnight Maha Jumbo Coil 10 34 GoodKnight Gold Flash refill 4 316 79
Mortein PowerBooster Coil 10 34 Good Knight Power
6 365 61
Activ+
Maxo A grade Coil 10 33
All Out refill 6 390 65
Source: Ambit Capital research
Maxo refill 4 280 70
Mortein refill 4+2 promo 288 48
Source: Ambit Capital research
Non-mosquito & personal repellent portfolio – Optionalities that GCPL can seek to achieve
While the mosquito portfolio forms the majority (~87%) of the HI category in India, the non-
mosquito portfolio (especially for roaches) and personal repellents also offer a significant
opportunity. Roaches are a common issue in Indian households (implying sizable TAM) and
products like aerosol have proved to be an effective solution. However, aerosol penetration is
still less than 5% (with HIT having ~90%+ market share) in India due to affordability and
March 28, 2022 Ambit Capital Pvt. Ltd. Page 16
Godrej Consumer
inconsistency of usage/need issues. While the category has huge potential, more innovation is
needed to make the price points more affordable to attract mass consumers. Personal Insect
Repellents (PIR) in India is still very nascent (~`1.8bn) with Dabur dominating the category
through Odomos (~80% market share). GCPL had launched a natural roll-on for kids but
achieved limited success due to low efficacy and limited parents concern on applying it on a
child’s body. While PIR has potential to become sizable, growing this category in India will
require much more investment in creating awareness and innovation.
Exhibit 25: Mosquito products form the majority of the HI market in India
Non-Mosquito
(majorly roaches), 13%
Mosquito , 87%
Exhibit 26: Innovation + higher ad spends + growth in adjacencies = Scope for penetration increase, category expansion and GCPL’s potential to gain
share
Affordability
Improve
and
efficacy
distribution
•Believe product •Consumer's
affordability and perception on
distribution is not product efficacy is
an issue; there low; this needs to
will be takers for change through
efficacious breakthrough
product innovation
Exhibit 27: Over the last decade GCPL’s bar soap has Exhibit 28: …compared to 9% CAGR for the overall bar grown at 10% CAGR… soap market
GCPL Soap Sales
25,000
Bar Soap Market size
250
20,000
200
` . mn
15,000
150
` . bn
10,000
100
5,000
50
0
FY11 FY16 FY21
0
FY11 FY16 FY21
Source: Company, Ambit Capital research Source: Euromonitor International Limited 2021 © All rights reserved, Ambit
Capital research; Euromonitor data is given in CY terms which has been converted
into FY terms
Exhibit 29: Wipro, Reckitt, GCPL and Patanjali have gained market share at the cost of HUL; HUL has lost Source: Ambit Capital research; Note – Grade 1
320bps market share in bar soaps since 2016 (TFM => 76%), Grade 2 (TFM 70% to 76%), Grade
3 (TFM 60% to 70%); TFM content for Pears and
market
Brand Company 2016 2017 2018 2019 2020 Dove is not available since its categorization is
share change
different
Santoor Wipro Consumer 10.0% 10.7% 11.4% 11.9% 11.7% 168bps
Lifebuoy HUL 13.4% 13.1% 12.2% 11.2% 11.0% -245bps Where will the ship pivot now?
Lux HUL 12.5% 12.2% 11.3% 10.4% 10.2% -236bps
Soaps has done well for GCPL. But
Dettol Reckitt Benckiser 7.7% 8.4% 9.1% 9.2% 9.4% 171bps
with 95%+ category penetration, we
Godrej No 1 GCPL 7.5% 7.5% 7.6% 7.7% 7.7% 27bps
believe growth may get restricted at
Dove HUL 5.1% 5.2% 5.5% 5.9% 6.0% 89bps
6-7% (vs 10% CAGR over the last
Pears HUL 3.8% 3.9% 4.1% 4.3% 4.5% 65bps decade) after a few years. With two
Cinthol GCPL 3.7% 3.6% 3.6% 3.7% 3.7% 6bps well-known brands in the soaps
Patanjali Patanjali 3.1% 3.2% 3.1% 3.0% 2.9% -18bps category, the question is – will GCPL
Vivel ITC 2.5% 2.5% 2.5% 2.5% 2.5% -3bps look to tap into the premium soap
Hamam HUL 2.2% 2.2% 2.2% 2.2% 2.3% 7bps category, either bar soaps or liquid
Source: Euromonitor International Limited 2021 © All rights reserved, Ambit Capital research body washes, or look to explore
Godrej No.1 commands ~8% market share in the bar soap market and is the leader in north adjacencies within largely personal
India with strong presence in Punjab, Haryana, Himachal Pradesh and Uttaranchal. Godrej No.1 care category? While at this point in
has held fort over the years despite increased competitive intensity due to several initiative’s time management has not guided for
taken over the years - (i) ad spends much lower (12% of sales which allows GCPL to plough back that, at an opportune time we believe
savings into promo packs (pioneer in this) and offer better price value proposition (Grade 1 management will likely pivot the ship
soap - refer exhibit 30); (ii) introducing soap variants as per the needs of the regional markets into expanding TAM. Thus, currently,
earlier than competitors (aloe and lime variants in North India); (iii) micro-marketing initiatives beyond FY25E, we are building ~7%
to focus on specific markets (e.g. higher lime variant in say Punjab state vs other north Indian revenue growth for the soaps
states etc). segment.
Cinthol has a strong presence in south India (particularly Tamil Nadu and Andhra Pradesh) with Share gains in bar soaps are
commendable, while maintaining this
~4% market share pan-India. Cinthol has kept its original variant largely unchanged since
momentum will like to hear
launch. In south India, Cinthol Original is considered a medicated soap and is recommended by
management’s strategy of slowly
dermatologists/doctors for skin problems, which leads to higher trust amongst consumers.
pivoting to premiumisation and
Exhibit 30: Godrej No.1 offers the best price-value proposition vs competitors in the mass/economy adjacencies.
segment
70 Soap Pricing
Grade
60 1
50
Grade Grade
` ./100gm
40 Grade
Grade 2 1
Grade 2
30 1 3
20
10
0
Lux
Pears
Dove
Lifebuo
Santoor
Nivea
Godrej
Cinthol
No.1
GCPL attempted to disrupt the handwash category through the launch of Mr. Magic, the
powder to liquid handwash, in 2018. Despite its value proposition (`6-7/100ml vs `12-13/100ml
for regular handwash) we understand that the product has not gained desired consumer
traction as Mr Magic is more watery vs thicker versions of competing hand washes (Dettol,
Lifebuoy etc) and is less scented. In order to expand TAM into male grooming, GCPL in 2018
attempted to launch a range of male grooming under brand Cinthol. However, considering
inconsistent brand investment and consumer resonance, management has put that on the
backburner for now. Hence, at this point we are not building any growth from those
optionalities.
Exhibit 33: Hair colour grew in double digits during the first half of the decade, but was flattish in the second
half
Exhibit 34: GCPL’s products straddle price points Exhibit 35: All brands compete at the same price points in shampoo hair colour except
Garnier
Product Company ` /sachet Product Company ` /sachet
Godrej Nupur Henna GCPL 10 Godrej Expert Shampoo
GCPL 25
Godrej Expert GCPL 25 Hair colour
Indica Shampoo Hair
Hygienic Research CavinKare 25
Streax Hair Colour Black 30 Colour
Institute
Streak Insta Shampoo Hygienic Research
Indica Crème Hair Colour CavinKare 30 25
Hair Colour Institute
Godrej Expert Rich Crème GCPL 33 Garnier Men Shampoo Colour L'Oréal 39
Garnier Black Naturals L'Oréal 39 Source: Amazon, Ambit Capital research
Godrej Expert Rich Crème
GCPL 40
Fashion Range
Garnier Colour Naturals
L'Oréal 49
Crème Riche
Source: Amazon, Ambit Capital research
(value brand that serves as an entry point for mass consumers). What may be required is higher
marketing spends, improving consumer awareness on product efficacy, ease of use etc, which
can improve probability of repeat purchase.
5,000 6,000
4,000 4,500
` mn
3,000
3,000
2,000
1,500
1,000
0 0
FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY18 FY19 FY20
Source: Company, Ambit Capital research; Source: Company, Ambit Capital research;
With Covid seeming to be largely behind and normalization of outdoor activities, we expect the
hair colour category to resume its growth journey. GCPL’s strategy of category development,
launch of new products and consumer upgradation from powder to crème-based formats should
aid growth.
Other brands
10,000
9,000
8,000
7,000
6,000
` . mn
5,000
4,000
3,000
2,000
1,000
0
FY16 FY17 FY18 FY19 FY20 FY21
Exhibit 39: Amongst the optionalities listed below, air care has the highest probability of success
Category growth Focus Compe- Probability of
Brand Category Products tition success
(2015-2020) level
Sachet, automatic spray machine (matic), spray, gels for
Aer Air care 10-11% High Med
home and car
Known for winter wear liquid detergent; Recently launched Overall laundry
Ezee Laundry care Mid High
Liquid detergent & fabric conditioner for regular clothes Care: 4-5%
Toilet/Surface care:
Protekt & Home & Personal Handwash, disinfectant spray, dish wash, floor and toilet
11-12% Low High
ProClean care cleaners, etc.
Dishwash: 7-8%
Source: Company, Ambit Capital research Note: - Strong; - Relatively Strong; - Average; - Relatively weak
Exhibit 41: Basis below framework, GCPL has higher probability of success in HI, soaps and air care
FY16-21
Probability of
Category revenue Past growth concerns How are they being addressed Competitive reaction What more can be done
success
CAGR
Limited thrust on Increase ad spends & branding; aspire to Largely operates as a Focus on personal repellent
HI 2% innovation, lower brand launch limited but relevant breakthrough challenger brand & deepen focus in aerosol
spends product Expanding share in range
No efforts made premium range where
Current focus is not on Premiumisation,
Soaps 4% towards premium GCPL is not competing
premiumisation /adjacencies adjacencies in overall
range and
Main competitor grooming segment
adjacencies
Limited initiatives Category development efforts to improve largely present in Expand hair oil-based hair
Hair colour 1% towards category penetration and drive sustainable revenue Urban, rest colour and natural hair
development growth fragmented play colour range at
Category development efforts to multiple price point
White spaces still improve penetration and drive Limited competition Improve product range,
Others
20% remain in air care sustainable revenue growth straddle across price points
(Air care, etc)
Source: Company, Ambit Capital research Note: - Strong; - Relatively Strong; - Average; - Relatively weak
These acquisitions led to increasing share of international business revenues from NIL in FY05 to
44% as at FY21 (reached ~50% in FY17). Within international business, as also reflected in
number of acquisitions, share of GAUM (Africa, USA and Middle
East) is the highest at 51% followed by Indonesia at 36% and LATAM & others at 13%.
Exhibit 43: 12 acquisitions between FY06-17 led to Exhibit 44: Revenue share of GAUM is the highest followed by
increasing share of IB Indonesia, however…
Ambit Capital Pvt. Ltd. Page 16
abhishek.raichura@ambit.co 2022-03-28 Monday
10:00:10
Share of International business revenues
% share
50 % Others,
13 %
40 %
Indonesia,
30 % 36 %
20 %
10 %
0%
FY05 FY07 FY09 FY12 FY16 FY19 FY21 GAUM,
51 %
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Exhibit 46: …despite capital employed remaining at ~64% over the last
Exhibit 45: …GAUM’s share of EBITDA has consistently been reducing… few years
80 % 43 % 80 %
30 %
43 %
60 % 60 % 66 % 64 %
64 %
40 % 40 %
59 % 60 %
20 % 44 % 20 %
25 % 24 % 25 %
0% 0%
FY17 FY19 FY21 FY17 FY19 FY21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Strategy of becoming an Indian MNC in emerging markets sounds exciting. But in the context of
operating challenges, geopolitical risks, inherent macro-economic challenges etc. it is not easy to
make it returns-accretive.
Exhibit 49: Standalone RoCE is in the 35-40% band; decline in CE turnover in IB led to moderating IB RoCE, which pulled
down overall RoCE
60 % 1.2
45 % 0.9
)
30 % 0.6 (x
15 % 0.3
0% 0.0
FY07 FY10 FY13 FY16 FY19 FY21
Source: Company, Ambit Capital research; Note – Balance sheet for IB has been built basis difference between Consol and Std;
RoCE is calculate as EBIT*(1-t) / Capital employed less Cash and equivalents
Exhibit 50: GAUM’s share of EBITDA has consistently been Exhibit 51: …despite capital employed remaining at reducing… ~64% over the last few
years
80 % 43 % 80 %
30 %
43 %
60 % 60 % 66 % 64 %
64 %
40 % 40 %
59 % 60 %
20 % 44 % 20 %
25 % 24 % 25 %
0% 0%
FY17 FY19 FY21 FY17 FY19 FY21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
For GCPL, India product basket is similar to Indonesia in terms of categories whereas is different
vis-à-vis GAUM and LATAM.
Exhibit 52: Limited cross pollination opportunities within GCPL’s different geographical
portfolios
GAUM Indonesia LATAM India
Ethnic hair colour, Hair extension, Household insecticides Household insecticides
Hair care & maintenance (89%) (35%) Hair colour (40%)
Personal care (4%) Air care (24%) Hair styling products Personal care (32%)
Others (6%) Others (26%) Hair fixing sprays Hair care (10%)
Personal care (13%) Depilatory products Air care (4%)
Others (14%)
Source: Company, Ambit Capital research
Exhibit 54: As inorganic acquisitions ebbed, revenue CAGR Exhibit 55: …which coupled with EBITDA margin moderated to mid-single digit…
compression lead to RoCE dilution
30 % 4%
15,000 3%
15 %
10,000 2%
5,000 0%
1%
0 -15 % 0%
FY16 FY17 FY18 FY19 FY20 FY21 FY16 FY17 FY18 FY19 FY20 FY21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research; Note – Calculated using
segmental data
While management does not disclose revenue contribution from each brand, we believe Darling
brands is the largest with ~50% of GAUM’s revenue. Hence, it would be crucial to understand
the hair extension market in Africa and USA. As per reports, global hair wigs, weaves and
extension market is USD6bn and is likely to grow at ~15% CAGR to reach USD13bn by 2026.
Growth of hair extension market is expected to be high owing to: (i) inherent fragility and
coarseness of hair of African origin population; (ii) increasing hair fall rate; (iii) increasing income
profile of middle income consumers; (iv) urban community looking for image makeover, etc.
Exhibit 56: GCPL is present in the large ~USD3bn hair extension market in USA and Africa
USA hair
extension market Animal hair -
- USD1bn 15 %
(approx)
Exhibit 57: With Evergreen products’ higher exposure to Exhibit 58: …vs Rebecca hair products which has barely USA, it has been able to clock ~9%
sales CAGR… clocked ~4% revenue CAGR in Africa
Revenues Revenue growth
Africa revenues Africa revenue growth
1,000 15 %
1,000 25 %
800 12 %
900 10 %
In mns, HK$
600 9%
In mns, CNY
800 -5 %
400 6%
700 -20 %
200 3%
600 -35 %
0 0%
2014 2015 2016 2017 2018 2019 2020 500 -50 %
2014 2015 2016 2017 2018 2019 2020
Source: World Bank, Ambit Capital research Source: World Bank, Ambit Capital research
Distribution maze
Informal retail is dominant across sub-Saharan Africa. As per reports, informal retailers sell 80%
of fast-moving consumer goods (FMCG) to African households. According to the United Nations
Economic Commission for Africa (UNECA), 90% of retail transactions in Africa happen through
informal channels. These informal transactions account for 70% of retail transactions in Kenya,
96% in Ghana, and 98% in Nigeria and Cameroon. Despite informal retail’s importance in driving
scale, it is uncoordinated, fragmented, and unstructured. Multiple players exist in retail supply
chains – manufacturers, distributors, sub-distributors, logistics providers, and retailers (refer
below exhibit) – but they operate in silos. Distribution networks are costly to build. With deep
pockets, large FMCG companies such as Coca-Cola, Unilever, and Nestle, have invested heavily
but still account for only 30% of volumes through their own network whereas the remaining
70% works through the sub-distributors network. These hold true largely for African markets ex-
South Africa where the saliency of e-com, MT and super markets is high.
Exhibit 59: Multiple layers in the FMCG distribution lead to disconnect between buyers and manufacturers, restricting brands to have visibility on end-
consumer demand
Profile of Dharnesh – Prior to joining GCPL, Dharnesh worked at Nestle for 15 years as CEO
Nestlé Indonesia, CEO Nestlé Nigeria,
Chairman Nestlé Nigeria Trust, Group Sales Director Nestlé
Southern Africa. Prior to Nestle, Dharnesh was associated with printing and textile industries in
South Africa for 15 years.
From FY20, i.e. the time Dharnesh took over as the CEO of GCPL’s GAUM, we see a change in
strategy by focusing on GTM strategy. The evidence of this is lowering dependence on
wholesalers, vs deploying more feet on street, to better gauge the competitive landscape at the
retail framework and seek better consumer insights.
Exhibit 61: New CEO’s strategy of focusing on improving GTM strategy bridges the missing link, in our view
i. Ramping up go-to-market efforts across Africa. ii. In Nigeria, where trade is largely unorganised and wholesale-led, we are scaling up reach through a
more intensive redistribution network. Focussing on driving higher same-store throughputs with improvements in range and quality of execution.
Generating demand through new product seeding models which will help initial retail penetration. iii. In Kenya, continued scaling up of distribution
through a combination of various models (sub-distributor, van sales, and wholesaleassist). Shifted focus from primary sales to secondary sales, through
strong partnerships with distributors and by monitoring the distributor ERP system. iv. In South Africa, we piloted a ‘Perfect Stores’ programme to
increase sales by enhancing shopper experience. v. The restructuring of salon channel in Africa will be a big focus. Salon education programmes are key
to building influence and generating demand in the dry hair care category. Pilots on the wet hair salon programme in Kenya have shown early success,
and we will be scaling this up. vi. In Africa, sales force automation has helped expand coverage and improve brand visibility across the subcontinent.
Following the roll-out across the general trade and salon channels, the focus will now be on scaling up distribution, extracting efficiencies and building
accountability.
FY21 Annual Report:
Dharnesh's
i. Undertaken a revised strategy shared with the Board in August 2020. As part of this, shifted to a centralised category management structure from a
strategy for geography-led one. We are ramping up our go-to-market efforts across Africa. ii. In Nigeria, where trade is largely unorganised and wholesale-led, we
GAUM market are scaling last-mile distribution through van, sub-distributor models, and salon advocacy. We also launched a door-to-door (D2D) sampling drive to
build demand and educate consumers on recently launched HI portfolio. This resulted in a significant shift in non-wholesale channel contribution. We
will continue the momentum in Nigeria and strengthen fundamentals in South Africa and Kenya. iii. In Africa, sales force automation has helped expand
coverage and improve brand visibility across the sub-continent. Following the roll-out across the general trade and salon channels, the focus will now
be on scaling up distribution, extracting efficiencies, and building accountability.
GAUM’s performance over the last few quarters after Dharnesh rolled out his new GTM strategy
increases the probability of the strategy’s success.
Exhibit 62: GAUM business reported double digit growth in Exhibit 63: …as Covid impact receded , growth has largely
only 4 of 10 quarters pre-Covid… remained in double digits
19
19
20
18
18
18
19
20
20
-5 %
QFY
QFY
QFY
QFY
QFY
QFY
QFY
QFY
QFY
QFY
21
21
21
22
22
22
QFY
QFY
QFY
QFY
QFY
QFY
2
3
-10 %
3
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Darling Spring Twist Crochet Hair Extensions (pack of 4) USD 29.99 African Pride Moisture Miracle Coconut Oil & Baobab Oil
USD 9.99 Leave-In Hair Cream (15 ounce)
Darling Jozi Locs Crochet Hair Extensions (pack of 1) USD 44.99 African Pride Moisture Miracle Hydrate & Hold Curl
USD 21
Defining Hair Gel (3 Pack, 18 ounce)
African Pride Anti Breakage Leave In conditioner (15
Other brands ounce) USD 9.99
-1% -50 %
-60 %
-5% Kenyan Shilling Nigerian Naira South African
FY18 FY19 FY20 FY21 Rand
Source: World Bank, Ambit Capital research Source: World Bank, Ambit Capital research
Exhibit 69: Indonesia business reported sales growth of Exhibit 70: …but with margin expansion and limited mere 4% CAGR over FY16-21…
incremental capital deployed, RoCE improved steadily
10 %
14,000
0%
12,000 5%
10,000 -15 % 0%
FY16 FY17 FY18 FY19 FY20 FY21 FY16 FY17 FY18 FY19 FY20 FY21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
The Indonesian FMCG market growth slowed down from 2017 (refer exhibit 71) for a variety of
reasons, including slow increase in minimum wages, weak agricultural commodity prices leading
to lower farm income etc.
Exhibit 71: Indonesia consumer goods industry growth started to Exhibit 72: …and revenue growth for Unilever Indonesia and GCPL (to
decelerate from 2015… some extent) too slowed
Consumer goods industry growth Unilever Indonesia rev growth GCPL Indonesia rev growth
12 % 15 %
10 %
8%
5%
4%
0%
0%
-5 %
-4 % -10 %
2015 2016 2017 2018 2019 2020* 2014 2015 2016 2017 2018 2019 2020
Source: Unilever Indonesia Annual Report, Ambit Capital research; Data for 2020 is Source: Unilever Indonesia, GCPL, Ambit Capital research
household consumption data
Exhibit 73: This led to massive compression in Unilever Indonesia’s Exhibit 74: Indonesia’s RTM largely similar to that of India but with
earnings multiple different channel growth rates
3 QCY20
60 x Unilever Indonesia 1yr Fwd P/E
Others, 7%
50 x Hyper/Super
markets, 7%
40 x
Mini
30 x markets,
19 %
20 x
10 x Traditional
trade, 67%
Feb-19
Feb-20
Feb-15
Feb-16
Feb-18
Feb-21
Feb-22
Feb-17
Aug-15
Aug-16
Aug-17
Aug-18
Aug-19
Aug-20
Aug-21
Source: Unilever Indonesia Annual Report, Ambit Capital research; Data for Source: Unilever Indonesia, GCPL, Ambit Capital research 2020 is household
consumption data
relevance in the geography. As depicted in the below exhibit, aerosol & LV constitute a larger
share of the Indonesian HI market at ~60%. Within that, we understand aerosol has the lion’s
share. HI is largely a three-player market in Indonesia with GCPL leading the category followed
by S C Johnson and Fumakilla. Basis management’s commentary, GCPL has been able to
increase its share in the HI category by 50-100bps over the last 3-4 years.
Exhibit 75: Market segmentation of Exhibit 76: …GCPL was largely present in Exhibit 77: …and with the launch of Indonesian HI
suggests… only 60% of the category before… HIT PIRAMIDA will enter the coil segment
% Coils & Personal %
Coil
repellant
30%
Aerosols 15%
& LV Aerosols
60 % Personal & LV
repellant 85 %
10%
Source: Company, Ambit Capital research Source: Company, Ambit Capital research Source: Company, Ambit Capital research
GCPL’s foray into the coil segment not only fills a white space but also offers a product in an
economy range which can attract low to mid-income consumers. With this, we expect GCPL to
not only strengthen its position in the HI category but also potentially sustain industry leading
growth of high single digit.
Air freshener (25-30% of Indonesia’s revenues) – Category growth to revive but only gradually
Air care is ~USD100mn category which has grown at 6-8% CAGR from 2015-2021. GCPL is the
market leader with brand ‘Stella’. Air care penetration in Indonesia is ~30% vs high single digit
for India and >50% for developed countries. Considering the higher category penetration (vs
India) and income impact on consumers post Covid, the air care category’s growth may remain
subdued in the near term. Also, as in many consumer categories, in an economic distress
scenario, there are always private labels which crop up. This happened in air care category in
Indonesia. Hence, we believe in the near term air care growth would remain weak for GCPL. But
in the mid to long term, we expect GCPL to be able to clock high single-digit revenue growth as
it works on the price-value equation, introducing more products and saliency of 40% of
revenues from the premium part of air fresheners.
Baby wipes (~15% of Indonesia’s revenues) – Need to sacrifice margins for growth
Baby wipes is ~USD150mn category and has grown at a mid-teen run-rate over the last 6-7
years. Here, too, GCPL is the market leader. But over the last 18-24 months, we understand
(corroborated by management commentary) it has lost some share largely due to aggression of
Kimberly Clark and Unicharm. We understand that Softex Indonesia was looking to sell its baby
care portfolio and hence from 2018 had become quite competitive in pricing and distribution of
its baby care range, including wet wipes. In 2020, Softex Indonesia was sold to Kimberly Clark
for a valuation of USD1.2bn. This strategy of Softex has been continued by Kimberly post
acquisition too. In the process, even competing brand Unicharm got aggressive with its pricing,
resulting in a lower profit pool for the category and GCPL losing some market share. Going
ahead, while management remains confident of clawing back lost market share due to
enhanced distribution and competitive pricing, we would wait for 2-3 quarters before looking to
build double-digit revenue growth in the segment.
Hygiene & hair colour (10-15% of Indonesia’s revenues) – Too nascent
This category which was born during Covid reached a brand size of ~`1.5bn in a year. During
Covid, GCPL launched multiple home hygiene products such as hand wash, sanitizer, soap, air &
surface sanitizer etc. However, as we enter the post-Covid era, we wonder what proportion of
the hygiene portfolio would remain relevant. While management believes “focusing on building
parts of hygiene portfolio especially soaps, powder to liquid hand wash are going to be much
more enduring even post Covid”, we do not echo that view. This would imply soft growth in the
postCovid era considering the high base. In FY17, by cross-pollinating from its Indian portfolio,
GCPL forayed into the hair colour range under brand NYU. We understand this brand’s saliency
is 2-3% to GCPL’s Indonesian revenues. The hair colour market in Indonesia is USD50mn with
Loreal, Mandom and Victoria Care having ~55% share. While hair colour is a small portfolio for
GCPL’s Indonesia business, it has the potential to leverage its category expertise of its India
operations. This can help it introduce new variants/products and colours. Distribution would be
critical in the salon/beauty channel for the brand to scale up.
Revamp of distribution is critical
Historically, GCPL’s retail focus was through the modern trade route (~70% revenue saliency)
followed by general trade (~28%) and e-com (~2%). Over the last 3-4 years, Indonesia’s retail
market has changed with the GT channel growing faster than MT. With this change in channel
dynamics, GCPL had to recalibrate its go-to-market strategy over the last few years.
Exhibit 78: GCPL’s strategy to revamp RTM has already been implemented; likely benefits should come from FY23E
Even in a recent interaction (27 Sept 2021) with investors/analysts, Akhil Chandra, Indonesia
cluster head, alluded that GCPL’s go-to-market strategy is to: (i) reach direct coverage of
200,000 outlets, which is appropriate considering that even Nestle Indonesia reaches ~250,000
outlets directly and (ii) activate wholesalers and do pilots with spreaders. Basis our interaction
with an expert, a re-calibrated go-tomarket was one of the missing links for GCPL, which is set to
be bridged. This should help GCPL ensure no sales loss due to non-product placement. With this,
GCPL would also be able to address competition issues in categories like wet wipes.
Exhibit 79: Indonesia does not have currency volatility Exhibit 80: … with last decadal median currency movement
issue as seen in Africa… vs INR largely flat
Indonesia CCY growth (%) Indonesia reported growth (%) 15 % % Depreciation vs INR
15% 10%
10 %
5%
5%
0%
0%
-5 % -5 %
-10 % -10 %
CY14
CY17
CY18
CY21
CY13
CY15
CY16
CY19
CY20
CY22
-15 %
FY18 FY19 FY20 FY21
Source: Company, Ambit Capital research Source: Bloomberg, World Bank, Ambit Capital research
Exhibit 81: Better growth in HI and hair colour will be offset by slower growth in hygiene and wet wipes
Category Category Market Growth levers Near term growth concerns, if any
CAGR position
HI 6-7% Leader Entry into coil segment None
Lower consumer disposable income
Air freshner 6-8% Leader Penetration led growth and rising share of private labels
Baby wipes Mid-teen Leader Competitive product pricing and High competitive intensity amongst
distribution expansion top 4-5 brands
High during Growth sustenance in soaps and Growth to moderate in sanitizer,
Hygiene FY20-22 N.A. hand wash surface cleaner and other hygiene
related products
Brand building and establishing Marginal
Cross pollinating products
Hair colour N.A. distribution in salon, beauty
player and
learnings
from
India
channels
Exhibit 83: Inorganic acquisitions led to debt + CE CAGR of Exhibit 84: …and net block/goodwill grew at a CAGR of 38% over FY05-21 on the liability
side... 36%/50% on the asset side
55,000
60,000
` mn
40,000 35,000
20,000 15,000
0
(5,000)
FY05 FY09 FY14 FY17 FY21 FY05 FY09 FY14 FY17 FY21
Source: Company, Ambit Capital research Source: Bloomberg, World Bank, Ambit Capital research
Now, however, a large part of capex is already undertaken (incremental capex more for
maintenance/automation). With no immediate M&A on the cards, we expect capital employed
CAGR of 10% over FY21-25E. This coupled with EBITDAM/EBIT expansion of 110bps/140bps over
FY21-25E should help RoCE expand to 34% in FY25E from 20% in FY21.
Godrej Consumer
Exhibit 85: India and Indonesia posted ~360bps/450bps Exhibit 86: …which led to GAUM’s share in EBITDA EBITDAM expansion over FY16-21…
dropping to 10% vs 19% in FY16
30 % 27 % 28 % 100 %
25 % 16 % 13 % 11 % 10 %
24 % 19 %
25 % 23 %
80 %
20 % 17 %
15 % 60 %
15 % 11 % 10 % 10 %
10 % 40 %
62 % 67 % 69 % 68 % 69 %
5% 20 %
0%
FY17 FY18 FY19 FY20 FY21 0%
FY17 FY18 FY19 FY20 FY21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Exhibit 87: Worst of margins seems to be behind... Exhibit 88: …we expect ~470bps EBITDAM expansion over FY21-25E
20 % GAUM
16 %
15 %
14 %
10 %
12 %
5%
10 %
0%
8%
FY17 FY18 FY19 FY20 FY21
FY21 FY22E FY23E FY24E FY25E
GAUM
Source: Company, Ambit Capital research Source: Bloomberg, World Bank, Ambit Capital research
Indonesian CPG companies in the band of 25-30% (refer below exhibit). Thus, as the business
wades through near-term RM inflation and competitive issues, we expect Indonesia margins to
hold on to 26-28% levels. We expect GCPL’s Indonesia margins to moderate to 26% in FY23E
(led by GM pressure), but expect a revival to ~27.5% by FY25E.
Exhibit 89: Indonesia’s EBITDAM likely to sustain at Exhibit 90: Other CPG companies in Indonesia too elevated 26-28% EBITDAM band
operate at 25-35% EBITDAM
27 %
35 %
26 %
25 % 30 %
24 %
23 % 25 %
22 %
20 %
FY17
FY18
FY19
FY20
FY21
FY24E
FY22E
FY23E
FY25E
Source: Company, Ambit Capital research Source: Bloomberg, Company, Ambit Capital research; Note – Industri
Jami’s business includes CPG, Ayurvedic personal care and F&B products
Exhibit 91: Over the last 6 years, India EBITAM Exhibit 92: Reversal of some of those cost items and GM improvement was aided by GM expansion,
lower ad spends pressure will mean EBITDAM improvement should only and employee cost, and some benefit of cost savings play out from FY24E
Freight
Ad spends
Employee cost
Other Expenses
EBITDAM FY16
EBITDAM FY21
21 %
20 %
FY16
FY17
FY18
FY19
FY20
FY21
FY24E
FY22E
FY23E
FY25E
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
India:
Improving penetration, innovation and increasing ad spends to
Home Care 12% 9% 10% 10% 10%
Ambit Capital Pvt. Ltd. Page 31
abhishek.raichura@ambit.co 2022-03-28 Monday 10:00:10
improve HI category growth rates
Market share gains in soaps, post Covid sales improvement in discretionary
Personal Care 17% 13% 11% 10% 10% categories of hair colour can lead to double digit
segment growth
IB:
GUAM 8% 20% 14% 12% 12% Improvement in execution of GTM strategy, expansion of wet hair
LATAM 19% 9% 9% 9% 9%
Gross margin (%) 55.3% 50.5% 51.5% 54.0% 55.0%
Ad spends (%) 6.6% 6.6% 7.3% 7.5% 7.5%
PAT growth (%) 15% -5% 12% 34% 18% GM and EBITDAM expansion from FY24E to lead to PAT CAGR of
13%
Cash flow statement
Operating cash flow 20,296 19,349 21,508 27,817 32,524
Free cash flow 18,658 17,737 19,396 25,205 29,412 With controlled capex, OCF largely used towards debt repayment
Gross borrowings 7,595 19,000 13,500 8,000 4,000
Ratios
Fixed asset turnover (x) 2.4 2.6 2.7 2.9 3.0 With capex largely behind, expect FA turnover to improve
RoCE (%) 20% 19% 22% 29% 34% EBIT margin improvement to drive RoCE improvement
Exhibit 94: We are lower than consensus for FY22E/23E on margins; with recent run-up in RM prices, we believe
consensus will cut margin estimates
Ambit estimates Consensus estimates vs consensus
` mn
FY22E FY23E FY24E FY22E FY23E FY24E FY22E FY23E FY24E
Revenues 123,792 137,920 152,428 122,910 135,146 149,364 1% 2% 2%
EBITDA 23,549 26,807 33,133 25,738 29,125 33,253 -9% -8% 0%
PAT 16,304 18,565 24,408 18,460 21,061 24,382 -12% -12% 0%
Source: Bloomberg, Ambit Capital research
India business – Penetration & premiumisation: GCPL will be able to improve penetration
across HI, air care and hair colour. In soaps, it will gradually pivot into premiumisation and
then adjacencies in body wash segment.
GAUM – GTM improvement & cross-pollination: Taking cognizance of hair care category
relevance and expected growth rate (early teens) and improvement in GTM, GCPL will be
able to easily defend its market share. Beyond that, as it looks to expand its HI range
leveraging on GCPL’s category expertise (leadership in India and Indonesia), we expect the
GAUM cluster to be able to maintain low double-digit growth.
Indonesia – Cross-pollination & adjacencies: Undertaking category development (like in
India) and recalibration of GTM strategy to expand presence in GT/convenience stores,
GCPL is under-indexed to medium to long-term growth vectors. This should yield high
single-digit growth over the medium to long term.
Near-term (FY21-25E) EBIT margin (including other income) expansion of 190bps will be a
function of 140bps EBITDAM expansion. Beyond that (FY25-41E) we remain conservative in
our EBIT margin estimates since the company will continuously undertake category
development activities. That would entail higher ATL and BTL spends, more feet on street,
higher innovation etc, all of which may drive higher operating cost. We are thus building
just 80bps EBIT margin expansion from FY25-41E.
We consider CoE of 12%. This is similar to that given to Tata Consumer (similar international
business saliency) and Britannia (risk of ICDs) and 50bps higher than the CoE used for HUL,
Dabur and Marico.
Exhibit 95: Revenue CAGR would be led from across Exhibit 96: Near-term EBIT margin expansion led by geographies viz. India,
GAUM and Indonesia GAUM EBITDAM improvement; post which EBIT margin expansion would be slim
24 %
Revenue CAGR EBIT CAGR
15 % 23 %
22 %
12 %
21 %
9%
20 %
6% 19 %
18 %
3%
17 %
0% FY16 FY21 FY25E FY31E FY41E E
FY16-21 FY21-25E FY25-41E BIT margin
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Exhibit 97: Scenario analysis with TG & CoE beyond two stages DCF Exhibit 98: … & scenario analysis of growth rates beyond explicit DCF
forecast period… forecast
Exhibit 99: FY18, FY19 and FY20 EPS estimates faced downgrades, which
moderated share price performance… Exhibit 100: ..and also led to P/E de-rating (below 3 years rolling
average multiple now)
Stock Price (LHS - in Rs) 2018 EPS Est (Rs )
2019 EPS Est (Rs ) 2020 EPS Est (Rs ) 1 yr fwd PE 3 yrs rolling avg
60
1,000 25
50
800 20
40
600 15
30
400 10
)
(x
20
200 5
10
0 0
0
Jul-14
Jul-15
Jul-16
Jul-17
Jul-18
Jul-19
Jul-20
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
Jan-20
Mar-13
Mar-15
Mar-16
Mar-18
Mar-19
Mar-21
Mar-22
Mar-11
Mar-12
Mar-14
Mar-17
Mar-20
Source: Bloomberg, Ambit Capital research;
Source: Ambit Capital research
Exhibit 101: GCPL’s valuation is below FMCG mean despite FY21-24E revenue/EPS growth being in the top quartile of the FMCG peer set
Exhibit 102: GCPL’s strategies aim to fix past issues; Exhibit 103: …thus near-term PAT CAGR should be healthy Dabur and Marico aim to not only
strengthen the core but for GCPL vs peers,
whilst being available at an attractive also valuation
seed newer categories… Marico
60 x
GCPL Dabur
Sustain
penetration - led Nestle
Category development/ growth in Saffola 50 x
TAM expansion
FY24 P/E
Build food Dabur HUL
Strengthening the core 40 x Marico
portfolio Tata
Increase ad Distribution spends, Sampling Consumer
expansion in rural
Revival of growth 30 x Britannia
Modern formats & GCPL
Aspire for break- packaging through in VAHO
changes 20 x
innovation
Sustain steady 10 % 15 % 20 % 25 % 30 %
especially in volume growth in
Healthcare PAT CAGR FY22-24E
core
Recalibrating
Revival of growth
GTM, especially in
in IB
IB
Source: Bloomberg, Ambit Capital research; Note - Moon chart indicates Source: Ambit Capital research probability of success;
Exhibit 104: Under Sudhir’s leadership, HUL’s F&R sales Exhibit 105: …company-level growth during FY16-20 by growth outpaced… ~110bps
80
70
60
50
40
30
` bn
20
10
0
FY16 FY17 FY18 FY19 FY20
Source: Company, Ambit Capital research Source: Company, Ambit Capital research
Despite Sudhir’s rich experience and splendid track record at HUL, the question is whether one
individual can change the fortunes of a company that has been built over several decades. To
answer this, we looked at how new CEOs in comparable FMCG companies in the recent past
have changed business strategies which led to relative share price outperformance. Britannia,
Nestle and Tata Consumer have seen
management changes over the last 5-6 years and clocked strong P/E re-rating, leading to
handsome shareholder returns.
Ambit Capital Pvt. Ltd. Page 36
abhishek.raichura@ambit.co 2022-03-28 Monday 10:00:10
Exhibit 106: Strategic changes undertaken by new MD/CEOs of below companies paved way for handsome
shareholder returns
Prior issues
Prior issues - Expat with limited Indian Prior issues
- No market-share gains FMCG experience - Inefficienct capital
- Margin compression - Focus on margins over allocation
- Weak distribution revenue - Poor distribution reach
- Limited innovation
Exhibit 107: Instances of how share price Exhibit 108: …of three FMCG Exhibit 109: …got re-rated by sheer and 1-year fwd P/E…
companies which new management… better execution of strategies
BRIT share price (Rs) NEST share price (in Rs) TATACONS share price (in Rs)
1 yr Fwd PE (RHS ) 1yr Fwd PE (RHS) 1 yr Fwd PE (RHS )
4,500 75 x 20,000 80x 900 60 x
60 x 15,000 60x 45 x
3,000 45 x 600
10,000 40x 30 x
1,500 30 x 300
15 x 5,000 20x 15 x
0 0x 0x 0 0x
0
May-19
Mar-20
Feb-18
Jul-18
Oct-19
Jun-21
Dec-18
Nov-21
Jan-21
Aug-20
Feb-14
Feb-17
Feb-18
Feb-20
Feb-21
Feb-13
Feb-15
Feb-16
Feb-19
Feb-22
Jan-18
Jan-16
Jan-17
Jan-19
Jan-20
Jan-21
Source: Company, Ambit Capital research Source: Company, Ambit Capital research Source: Company, Ambit Capital research
So we believe GCPL’s new MD & CEO too is poised to bring strategic changes in the way
business segments and geographies are looked at, which can lead to potential P/E re-rating –
the extent of which could defer nevertheless!
Exhibit 110: Sudhir’s strategy refresh talks about category development initiatives; executing it well can strengthen
growth longevity and leadership position
Current Issues
- Limited innovation and cut back on ad spends;
defocussed from core in Indonesia.
- Improve GTM in GAUM and Indonesia.
- Drive cross pollination benefits.
GCPL’s management team is a blend of new relevant experienced team members coupled with
old hands with vintage.
Exhibit 112: Blend of old GCPL team members working alongside new MD & CEO and head of GAUM cluster
Years with
Name Designation Background
GCPL
Prior to this, he was the Executive Director for Foods & Refreshments at HUL. During his 22year stint at
Managing Director and HUL, he led teams across several categories and functions in India, Europe, South East Asia, and Africa.
Sudhir Sitapati <1
CEO MBA from IIM, Ahmedabad and a B.Sc. in Math with Economics Honours from St. Xavier’s College,
Mumbai.
In previous role at GCPL, he was CFO for the India & SAARC cluster. Prior to GCPL, he has worked at
Sameer Shah CFO 16 PepsiCo and General Mills.
A Chartered Accountant and has specialised in Treasury Management from CFA Institute.
Prior to this, he spent ~16 years at Nestle (Africa & South East Asia) in key leadership positions. He was the
Business Head - President Director and CEO of PT Nestle Indonesia and prior to that MD and CEO of Nestle Nigeria.
Dharnesh Gordhon Africa, USA & Middle <2 Holds an MBA and a Bachelor’s degree in Arts (Honours). Has completed PED from IMD Lausanne and LDP
East from London Business School. Also, has a Diploma in Higher Education and is a Chartered Marketer.
Has over two decades of experience in FMCG and OTC categories across the UK, Southeast Asia and India
Akhil Chandra Business Head - ASEAN 5 with GSK Consumer Healthcare and Reckitt Benckiser Plc.
ESG
Most of the large FMCG companies have always scored in the top quartile of the ESG
parameters. On Environment, GCPL has given targets that it aspires to achieve whereas Dabur
and Marico have largely shied away from giving targets especially in GHG emission and
renewable energy target. On Social and Governance, we assign Green flags to all three
companies. This said, GCPL score better on Independent directors with >10 years’ experience
(refer below exhibit).
Exhibit 113: GCPL scores well on Environment and Independent directors and is largely in line with FMCG peers on other aspects
Carbon/GHG and
zero emission target Achieve scope 1 & 2 carbon neutrality by
FY26;
In FY21, reduced specific GHG emissions by Commitment to reduce Reduce GHG emission intensity
~37% vs FY11 carbon footprint (Scope 1 & 2) by 75% from FY13
Plastic waste target 100% of the packaging material be recyclable, reusable or compostable by Plastic neutral
by collecting, processing &
FY25; Reduce packaging recycling 100% of the plastic waste 100% recyclable, reusable or
consumption/unit of production by 20% generated from packaging in FY22 & use at compostable
least 10% PCR content packaging portfolio by 2025
25%/56.5% of white-collar/blue-collar Females across India functions: 24% Gender diversity (managers &
Gender diversity team members are women; 21% women Marketing - 26%, R&D Centre - 30%, above); 58% of employees in Marketing,
in senior leadership roles Finance - 19% R&D, HR are women
FY21: 0.51 Injury rate, 3 Disabling FY21: 0.29 All Injury Rate & four FY21 Incidents: 3 Lost Time Injury , 21
Safety related incidents, 1 Fatality, 21 Lost Time Injury major incidents First Aid Case, 3 Medical Treatment; Zero
fatalities since 4 years
Governance GREEN FLAG
% of Independent directors 50% 56% 54%
No. Independent directors
2 out of 6 4 out of 7 3 out of 5
>10yrs
GTM strategy for GAUM: Post diagnosing the true problem of GTM in the GAUM cluster,
we see high possibility of success in that cluster. We thus build 17% sales CAGR in GAUM
over FY21-23E vs 6% over FY17-21.
Failure to revive growth in HI and hair colour: HI and hair colour have grown at just ~2%
and 1% CAGR respectively over FY16-21 due to competition from illegal incense sticks and
slowdown in discretionary categories due to Covid. Our high single-digit growth estimate is
built on the premise of GCPL launching a breakthrough product in HI and revival in
discretionary spends for hair colour growth.
International business: Key strategy change required to be executed is reworking the GTM
strategy. While this is being undertaken by the management, in case the desired success is
not achieved then 12% CAGR estimated over FY2125E may not play out.
Macro-economic and currency risks: GCPL derives 45% of its revenues from its
international business which has high exposure to emerging market economies such as
Indonesia, Africa and LATAM. In the past, Africa witnessed currency depreciation issues,
which continues to be a risk. Indonesia is more stable in terms of currency but poses risks in
terms of macro-economic slowdown.
Exhibit 114: Forensic accounting score contributors Exhibit 115: Forensic score percentile to universe and sector
Financials - Consolidated
Balance Sheet
Year to March FY20 FY21 FY22E FY23E FY24E
Shareholders' equity 1,022 1,023 1,023 1,023 1,023
Reserves & surpluses 77,961 93,367 103,964 115,818 131,683
Total Networth 78,984 94,389 104,987 116,840 132,706
Debt 26,637 7,595 19,000 13,500 8,000
Other long term liabilities 72 69 69 69 69
Deferred tax liability (5,701) (6,378) (6,378) (6,378) (6,378)
Total liabilities 99,992 95,675 117,678 124,032 134,397
Gross block 45,502 46,613 48,225 50,337 52,949
Net block 38,921 37,749 37,230 37,026 37,210
CWIP 570 574 574 574 574
Goodwill 53,393 51,299 51,299 51,299 51,299
Investments 6,720 6,791 6,791 6,791 6,791
Cash & equivalents 7,702 6,722 30,157 37,671 48,833
Debtors 11,573 10,045 11,275 12,562 13,883
Inventory 17,031 17,163 19,264 21,463 23,721
Other current assets 7,193 5,718 6,418 7,150 7,903
Total current assets 43,498 39,647 67,115 78,846 94,339
Current liabilities 41,381 38,514 43,230 48,164 53,230
Provisions 1,729 1,871 2,100 2,340 2,586
Total current liabilities 43,110 40,385 45,330 50,504 55,817
Net current assets 388 (738) 21,784 28,342 38,523
Total assets 99,992 95,675 117,678 124,032 134,397
Source: Company, Ambit Capital research
Income statement
Year to March FY20 FY21 FY22E FY23E FY24E
Operating income 99,108 110,286 123,792 137,920 152,428
Gross Profit 56,491 60,992 62,515 71,029 82,311
Employee costs 10,188 11,233 11,389 12,413 13,566
Ad Spends 7,391 7,332 8,170 10,068 11,432
Other expenses 17,481 18,544 19,406 22,154 24,180
EBITDA 21,430 23,883 23,549 26,393 33,133
Depreciation 1,973 2,039 2,131 2,316 2,427
EBIT 19,457 21,844 21,418 24,077 30,706
Interest expenditure 2,174 1,266 1,795 2,113 1,075
Other income 1,123 671 885 974 1,071
Adjusted PBT 18,406 21,248 20,509 22,939 30,702
Tax 2,638 3,595 4,204 4,702 6,294
Net profit 15,768 17,653 16,304 18,236 24,408
% growth 0.5% 15.4% -3.5% 11.8% 33.8%
Extraordinaries (802) (445) - - -
Adjusted Consolidated net profit 15,768 17,653 16,304 18,236 24,408
Reported Consolidated net profit 14,965 17,208 16,304 18,236 24,408
Source: Company, Ambit Capital research
Ratio analysis
Year to March FY20 FY21 FY22E FY23E FY24E
Gross margin (%) 57.0% 55.3% 50.5% 51.5% 54.0%
EBITDA margin (%) 21.6% 21.7% 19.0% 19.1% 21.7%
EBIT margin (%) 19.6% 19.8% 17.3% 17.5% 20.1%
Net profit margin (%) 15.9% 16.0% 13.2% 13.2% 16.0%
Dividend payout ratio (%) 62.5% 0.0% 35.0% 35.0% 35.0%
Net debt: equity (x) 0.2 0.0 (0.1) (0.2) (0.3)
Working capital days (26.6) (24.4) (24.4) (24.4) (24.4)
Gross block turnover (x) 2.2 2.4 2.6 2.7 2.9
RoCE (%) 18.7% 20.2% 19.4% 22.1% 28.6%
RoE (%) 20.8% 20.4% 16.4% 16.4% 19.6%
Source: Company, Ambit Capital research
Valuation parameters
Year to March FY20 FY21 FY22E FY23E FY24E
EPS (`) 15.4 17.3 15.9 17.8 23.9
Diluted EPS (`) 15.4 17.3 15.9 17.8 23.9
Book value per share (`) 77 92 103 114 130
Dividend per share (`) 8.0 - 5.6 6.2 8.4
P/E (x) 44 40 43 38 29
P/BV (x) 9 7 7 6 5
EV/EBITDA (x) 34 29 29 26 20
Price/Sales (x) 7 6 6 5 5
Source: Company, Ambit Capital research
Nitin Bhasin - Head of Research Strategy / Accounting / Home Building / Consumer Durables (022) 66233241 nitin.bhasin@ambit.co
Ajit Kumar, CFA, FRM Banking / Financial Services (022) 66233252 ajit.kumar@ambit.co
Alok Shah, CFA Consumer Staples (022) 66233259 alok.shah@ambit.co
Amandeep Singh Grover Mid/Small-Caps / Hotels / Real Estate / Aviation (022) 66233082 amandeep.grover@ambit.co
Ankit Gor Mid-Caps / Chemicals / Textiles / Packaging (022) 66233132 ankit.gor@ambit.co
Ashish Kanodia, CFA Consumer Discretionary (022) 66233264 ashish.kanodia@ambit.co
Ashwin Mehta, CFA Technology (022) 66233295 ashwin.mehta@ambit.co
Bharat Arora, CFA Strategy (022) 66233278 bharat.arora@ambit.co
Dhruv Jain Mid-Caps / Home Building / Consumer Durables (022) 66233177 dhruv.jain@ambit.co
Eashaan Nair Economy / Strategy (022) 66233033 eashaan.nair@ambit.co
Gaurav Jhunjhunuwala Media / Telecom / Oil & Gas (022) 66233227 gaurav.jhunjhunuwala@ambit.co
Jaiveer Shekhawat Mid/Small-Caps (022) 66233021 jaiveer.shekhawat@ambit.co
Jashandeep Chadha, CFA Metals & Mining / Cement (022) 66233246 jashandeep.chadha@ambit.co
Karan Khanna, CFA Mid/Small-Caps / Hotels / Real Estate / Aviation (022) 66233251 karan.khanna@ambit.co
Karan Kokane, CFA Automobiles / Auto Ancillaries (022) 66233028 karan.kokane@ambit.co
Kumar Saumya Chemicals (022) 66233242 kumar.saumya@ambit.co
Namant Satiya, CFA Consumer Staples (022) 66233259 namant.satiya@ambit.co
Nancy Gahlot Strategy / Forensic Accounting (022) 66233149 nancy.gahlot@ambit.co
Pankaj Agarwal, CFA Banking / Financial Services (022) 66233206 pankaj.agarwal@ambit.co
Parth Majithia Strategy / Forensic Accounting (022) 66233149 parth.majithia@ambit.co
Pratik Matkar Banking / Financial Services (022) 66233252 pratik.matkar@ambit.co
Prashant Mittal Technology / Internet (022) 66233295 prashant.mittal@ambit.co
Prashant Nair, CFA Healthcare (022) 66233041 prashant.nair@ambit.co
Satyadeep Jain, CFA Metals & Mining / Cement (022) 66233246 satyadeep.jain@ambit.co
Sumit Shekhar Economy / Strategy (022) 66233229 sumit.shekhar@ambit.co
Vamshi Krishna Utterker Technology (022) 66233047 vamshikrishna.utterker@ambit.co
Vinit Powle Strategy / Forensic Accounting (022) 66233149 vinit.powle@ambit.co
Vivekanand Subbaraman, CFA Media / Telecom / Oil & Gas (022) 66233261 vivekanand.s@ambit.co
Sales
Name Regions Desk-Phone E-mail
Dhiraj Agarwal - MD & Head of Sales India (022) 66233253 dhiraj.agarwal@ambit.co
Bhavin Shah India (022) 66233186 bhavin.shah@ambit.co
Dharmen Shah India / Asia (022) 66233289 dharmen.shah@ambit.co
Abhishek Raichura UK & Europe (022) 66233287 abhishek.raichura@ambit.co
Pranav Verma Asia (022) 66233214 pranav.verma@ambit.co
Shiva Kartik India (022) 66233299 shiva.kartik@ambit.co
Soumya Agarwal India (022) 66233062 soumya.agarwal@ambit.co
USA / Canada
1,200
1,000
800
600
400
200
0
May-19
Mar-20
May-20
Mar-21
May-21
Mar-22
Mar-19
Jul-19
Jul-20
Jul-21
Sep-19
Sep-20
Sep-21
Nov-20
Nov-19
Jan-20
Jan-21
Nov-21
Jan-22
Godrej Consumer Products Ltd
Explanation of Investment Rating - Our target prices are with a 12-month perspective. Returns stated are our internal benchmark
Investment Rating Expected return (over 12-month)
BUY We expect this stock to deliver more than 10% returns over the next12 month
SELL We expect this stock to deliver less than or equal to 10 % returns over the next 12 months
UNDER REVIEW We have coverage on the stock but we have suspended our estimates, TP and recommendation for the time being NOT
NOT RATED We do not have any forward-looking estimates, valuation, or recommendation for the stock.
POSITIVE We have a positive view on the sector and most of stocks under our coverage in the sector are BUYs
NEGATIVE We have a negative view on the sector and most of stocks under our coverage in the sector are SELLs
NO STANCE We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation
Note: At certain times the Rating may not be in sync with the description above as the stock prices can be volatile and analysts can take time to react to development.
Disclaimer
This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Ambit Capital Private Ltd. Ambit Capital Private Ltd. research is disseminated and available primarily electronically, and,
in some cases, in printed form. The following Disclosures are being made in compliance with the SEBI (Research Analysts) Regulations, 2014 (herein after referred to as the Regulations).
Disclosures
Ambit Capital Private Limited (“Ambit Capital or Ambit”) is a SEBI Registered Research Analyst having registration number INH000000313. Ambit Capital, the Research Entity (RE) as defined in the Regulations, is also
engaged in the business of providing Stock broking Services, Portfolio Management Services, Depository Participant Services, distribution of Mutual Funds and various financial products. Ambit Capital is a subsidiary
company of Ambit Private Limited. The details of associate entities of Ambit Capital are available on its website.
Ambit Capital makes its best endeavor to ensure that the research analyst(s) use current, reliable, comprehensive information and obtain such information from sources which the analyst(s) believes to be reliable.
However, such information has not been independently verified by Ambit Capital and/or the analyst(s) and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information
obtained from third parties. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to
be an authority on the subject. Ambit Capital and its affiliates/ group entities may or may not subscribe to any and/ or all the views expressed herein and the statements made herein by the research analyst may differ
from or be contrary to views held by other businesses within the Ambit group.
This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this Research Report or with the terms of this Disclaimer, your sole and
exclusive remedy is to stop using this Research Report and Ambit Capital or its affiliates shall not be responsible and/ or liable for any direct/consequential loss howsoever directly or indirectly, from any use of this
Research Report.
If this Research Report is received by any client of Ambit Capital or its affiliates, the relationship of Ambit Capital/its affiliate with such client will continue to be governed by the existing terms and conditions in place
between Ambit Capital/ such affiliates and the client.
This Research Report is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied in whole or in part, for any
purpose. Neither this Research Report nor any copy of it may be taken or transmitted or distributed, directly or indirectly within India or into any other country including United States (to US Persons), Canada or Japan or to
any resident thereof. The distribution of this Research Report in other jurisdictions may be strictly restricted and/ or prohibited by law or contract, and persons into whose possession this Research Report comes should
aware of and take note of such restrictions.
Ambit Capital declares that neither its activities were suspended nor did it default with any stock exchange with whom it is registered since inception. Ambit Capital has not been debarred from doing business by any Stock
Exchange, SEBI, Depository or other Regulated Authorities, nor has the certificate of registration been cancelled by SEBI at any point in time.
Apart from the case of Manappuram Finance Ltd. where Ambit Capital settled the matter with SEBI without accepting or denying any guilt, there is no material disciplinary action that has been taken by any regulatory
authority impacting research activities of Ambit Capital.
A graph of daily closing prices of securities is available at www.nseindia.com and www.bseindia.com
THIS RESEARCH REPORT IS BEING DISTRIBUTED IN THE US TO MAJOR INSTITUTIONAL INVESTORS UNDER RLE 15a-6 AND UNDER A GLOBAL BRAND OF AMBIT AMERICA AND AMBIT CAPITAL PRIVATE LTD.
The Ambit Capital research report is solely a product of Ambit Capital Private Ltd. and may be used for general information only. The legal entity preparing this research report is not registered as a broker-dealer in the
United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and/or the independence of research analysts.
Ambit Capital is the employer of the research analyst(s) who has prepared the research report.
Any subsequent transactions in securities discussed in the research reports should be effected through Ambit America Inc. (“Ambit America”).
Ambit America Inc. does not accept or receive any compensation of any kind directly from US Institutional Investors for the dissemination of the Ambit Capital research reports. However, Ambit Capital Private Ltd. has
entered into an agreement with Ambit America Inc. which includes payment for sourcing new MUSSI and service existing clients based out of USA.
Analyst(s) preparing this report are resident outside the United States and are not associated persons or employees of any US regulated broker-dealer. Therefore the analyst(s) may not be subject to Rule 2711 restrictions
on communications with a subject company, public appearances and trading securities held by the research analyst.
In the United States, this research report is available for distribution to major U.S. institutional investors, as defined in Rule 15a – 6 under the Securities Exchange Act of 1934. Additionally, this research report is available to
a limited number of individuals as Globally Branded research, as defined in FINRA Rule 2241. This research report is distributed in the United States by Ambit America Inc., a U.S. registered broker and dealer and a member
of FINRA. Ambit America Inc., a US registered broker-dealer, accepts responsibility for this research report and its dissemination in the United States.
This Ambit Capital research report is not intended for any other persons in the USA. All major U.S. institutional investors or persons outside the United States, having received this Ambit Capital research report shall neither
distribute the original nor a copy to any other person in the United States. In order to receive any additional information about or to effect a transaction in any security or financial instrument mentioned herein, please
contact a registered representative of Ambit America Inc., by phone at 646 793 6001 or by mail at 370, Lexington Avenue, Suite 803, New York, 10017. This material should not be construed as a solicitation or
recommendation to use Ambit Capital to effect transactions in any security mentioned herein.
This document does not constitute an offer of, or an invitation by or on behalf of Ambit Capital or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been
obtained from published information and other sources, which Ambit Capital or its Affiliates consider to be reliable. None of Ambit Capital accepts any liability or responsibility whatsoever for the accuracy or completeness
of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly
higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may
also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.
Ambit America Inc. or its affiliates or the principals or employees of Ambit Group may have or have had positions, may “beneficially own” as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of
the equity securities or may conduct or may have conducted market-making activities or otherwise act or have acted as principal in transactions in any of these securities or instruments referred to herein.
Ambit America Inc. or its affiliates or the principals or employees of Ambit Group may have managed or co-managed a public offering of securities or received compensation for investment banking services or expects to
receive or intends to seek compensation for investment banking or consulting services or serve or have served as a director or a supervisory board member of a company referred to in this research report.
As of the date of this research report Ambit America Inc. does not make a market in the security reflected in this research report.
Analyst(s) Certification
The analyst(s) authoring this research report hereby certifies that the views expressed in this research report accurately reflect such research analyst's personal views about the subject securities and issuers and that no
part of his or her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report.
The analyst (s) has/have not served as an officer, director or employee of the subject company in the last 12 months period ending on the last day of the month immediately preceding the date of publication of this
research report.
The analyst(s) does not hold one percent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report.
Research Analyst views on Subject Company may vary based on fundamental research and technical research. Proprietary trading desk of Ambit Capital or its associates/group companies maintains arm’s length distance
with the research team as all the activities are segregated from Ambit Capital research activity and therefore it can have an independent views with regards to Subject Company for which research team have expressed
their views.
Registered Office Address: Ambit Capital Private Limited, 449, Ambit House, Senapati Bapat Marg, Lower Parel, Mumbai-400013
Compliance Officer Details: Sanjay Shah, Email id: compliance@ambit.co, Contact Number: 91 22 68601965